ArticleWorld journal of surgical oncology2025
Long-term survival outcome of portal vein embolization in patients with perihilar cholangiocarcinoma: a retrospective cohort study.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPerihilar cholangiocarcinoma (CCA) often requires extended hepatectomy for curative treatment, especially in Bismuth type III–IV. However, the risk of post-hepatectomy liver failure (PHLF) cannot be ignored. Portal vein embolization (PVE) is a preoperative optimization method that reduces risk of PHLF, and improves surgical safety. This study investigated the impact of PVE on surgical outcomes and long-term survival in patients with Bismuth type III-IV perihilar CCA.
methodsWe retrospectively reviewed the data of 137 patients diagnosed with Bismuth type III–IV perihilar CCA between April 2011 and August 2021. Among 137 patients, 88 were included in the analyses and divided into three groups: resection without PVE (group A); resection after PVE (group B); and no resection after PVE (group C). The main outcomes of this study were surgical outcomes and long-term survival outcomes of each group. Survival analyses were performed using inverse probability treatment weighting (IPTW) and Cox regression analysis stratified by surgical resection.
resultsAmong 88 patients, 18 underwent resection without PVE (group A), 55 underwent resection after PVE (group B), and 15 did not proceed to surgery after PVE (group C). There was no significant difference in median recurrence-free survival (RFS) and overall survival (OS) between groups A and B (mRFS 11.9 vs. 18.1 months, P = 0.099; mOS 18.9 vs. 24.8 months; P = 0.454) after IPTW. However, a significant difference was found in median OS between groups B and C (25.9 vs. 10.2 months; P = 0.002). In the stratified Cox regression analysis in groups B and C, age (adjusted hazard ratio [aHR] 1.979ㅡ13.208), and percentage of future liver remnant after PVE (post-PVE FLR; aHR 0.160ㅡ0.744) were associated with OS regardless of surgical resection.
conclusionsPVE reduces the risk of post-hepatectomy liver failure and enables extended hepatectomy without comparing oncologic outcomes. Furthermore, in groups that underwent PVE, post-PVE measured FLR was an independent prognostic factor of OS, regardless of surgical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.